Contact Us

Want to Get in Touch?

We’d love to hear from you! Fill out the form with your questions or comments, and a member of our team will get in touch with you.

Contact Us

Glaukos will use the information you provide on this form to be in touch with you.

Consent(Required)

By checking this box and electing to submit this form with your personal data, you confirm that you are at least 18 years old and that you have read and accept the terms of our Privacy Policy. Glaukos will use the information you provide on this form to provide product updates and other promotional materials. Should you change your mind, you may unsubscribe using the link in the footer of any email you receive from us.

I agree.*(Required)

Name*(Required)

First Last

Email*(Required)

Zip Code*(Required)

Do you have a question related to:*(Required)

Glaukos values and respects your privacy and will not disclose information about you or your company to any third party.

Phone

This field is for validation purposes and should be left unchanged.

PM-US-0602

INDICATION FOR USE
The iStent inject^® W Trabecular Micro-Bypass System Model G2-W is indicated for use in conjunction with cataract surgery for the reduction of intraocular pressure (IOP) in adult patients with mild-to-moderate primary open-angle glaucoma.

CONTRAINDICATIONS
The iStent inject^® W is contraindicated in eyes with angle-closure glaucoma, traumatic, malignant, uveitic, or neovascular glaucoma, discernible congenital anomalies of the anterior chamber (AC) angle, retrobulbar tumor, thyroid eye disease, or Sturge-Weber Syndrome or any other type of condition that may cause elevated episcleral venous pressure.

WARNINGS
Gonioscopy should be performed prior to surgery to exclude congenital anomalies of the angle, PAS, rubeosis, or conditions that would prohibit adequate visualization of the angle that could lead to improper placement of the stent and pose a hazard.

MRI INFORMATION
The iStent inject^® W is MR-Conditional, i.e., the device is safe for use in a specified MR environment under specified conditions; please see Directions for Use (DFU) label for details.

PRECAUTIONS
The surgeon should monitor the patient postoperatively for proper maintenance of intraocular pressure (IOP). The safety and effectiveness of the iStent inject^® W have not been established as an alternative to the primary treatment of glaucoma with medications, in children, in eyes with significant prior trauma, abnormal anterior segment, chronic inflammation, prior glaucoma surgery (except SLT performed > 90 days preoperative), glaucoma associated with vascular disorders, pseudoexfoliative, pigmentary or other secondary open-angle glaucomas, pseudophakic eyes, phakic eyes without concomitant cataract surgery or with complicated cataract surgery, eyes with medicated intraocular pressure (IOP) > 24 mmHg or unmedicated intraocular pressure (IOP) < 21 mmHg or > 36 mmHg, or for implantation of more or less than two stents.

ADVERSE EVENTS
Common postoperative adverse events reported in the iStent inject^® randomized pivotal trial included stent obstruction (6.2%), intraocular inflammation (5.7% for iStent inject® vs. 4.2% for cataract surgery only), secondary surgical intervention (5.4% vs. 5.0%) and BCVA loss ≥ 2 lines ≥ 3 months (2.6% vs. 4.2%).

CAUTION
Federal law restricts this device to sale by, or on the order of, a physician. Please see DFU for a complete list of contraindications, warnings, precautions, and adverse events.

Text Optimizer